Clinical trials: Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and…
- Trial name
- NCT04458688
- Testing
- Observation of Ocrelizumab as Treatment in RRMS Patients
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wayne State University
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01433250
- Testing
- AIN457
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Relapse Remitting Multiple Sclerosis
Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later.
- Trial name
- STAT (NCT07878923)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Multiple Sclerosis
MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
This is a prospective, multicenter, open label, uncontrolled, non-interventional, single arm study to measure treatment satisfaction of relapsing remitting MS (RRMS) participants on Rebif after discontinuing initial first-line…
- Trial name
- MESTRE-MS (NCT02949908)
- Testing
- Rebif
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).
- Trial name
- NCT02601885
- Testing
- ABT-555
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- AbbVie
Multiple Sclerosis
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
This 4 month, open-label study will evaluate the safety and tolerability of fingolimod 0.5 mg in patients with relapsing-remitting multiple sclerosis (RRMS) and generate additional data in Multiple Sclerosis (MS) patient…
- Trial name
- NCT01497262
- Testing
- Fingolimod
- Where
- 29 sites in Argentina, Brazil and 6 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.
- Trial name
- NCT02326935
- Testing
- Autologous adipose derived mesenchymal cells
- Where
- Cayman Islands
- Volunteers
- 2 people
- Sponsor
- American CryoStem Corporation
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Relapsing Remitting Multiple Sclerosis
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of this study is to evaluate the safety and efficacy of NU100 in patients with relapsing remitting multiple sclerosis (RRMS) as compared to placebo and an active comparator.
- Trial name
- NCT01464905
- Testing
- NU100, rhIFN beta-1b
- Where
- 12 sites in Belarus, Bulgaria and 10 more
- Volunteers
- 500 people
- Sponsor
- Nuron Biotech Inc.
Multiple Sclerosis
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week…
- Trial name
- DreaMS (NCT01226745)
- Testing
- ONO-4641
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 340 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
The purpose of the study is to describe the safety profile of fingolimod in the Taiwanese multiple sclerosis population. This study aims to collect the safety data in patients newly initiated on fingolimod for one year.
- Trial name
- SPRING (NCT04480853)
- Testing
- Fingolimod
- Where
- 6 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity
Cognitive dysfunction is frequent in patients with multiple sclerosis (MS) and to date, there are no available treatments to improve cognition in this patient population.
- Trial name
- AERCONN (NCT02005237)
- Testing
- Aerobic Exercise
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis, Relapsing-Remitting
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
Study to evaluate the effectiveness of ofatumumab in Italian RRMS patients in the real-life setting.
- Trial name
- NCT06345157
- Testing
- Ofatumumab
- Where
- 31 sites in Italy
- Volunteers
- 379 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting
Exercise Effects in Multiple Sclerosis
A growing body of work suggests that regular exercise can support symptom management and improve physical function for people living with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Chronic Progressive
- Trial name
- NCT05496881
- Testing
- Exercise Group 1, Exercise Group 2, Exercise Group 3
- Where
- Canada
- Volunteers
- 69 people
- Sponsor
- University of Regina
Relapsing Remitting Multiple Sclerosis
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
The incidence of autoimmune conditions is at least 2-3 times higher in Multiple Sclerosis population than in general population. These MS patients category response unfavorably to the Interferon.
- Trial name
- NCT01456416
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Relapsing Remitting Multiple Sclerosis
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
This study consisted of a two year dose blinded phase during which patients received one of five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched to open label treatment with siponimod 2mg…
- Trial name
- NCT01185821
- Testing
- BAF312
- Where
- 46 sites in United States, Canada and 10 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R…
- Trial name
- CHOLINE (NCT01198132)
- Testing
- Cholecalciferol (Vitamin D3), Rebif
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- ReWRAP (NCT04002934)
- Testing
- Bazedoxifene Acetate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Riley Bove, MD